Michael E. Williams

Byrd S. Leavell Professor of Medicine: Hematology and Oncology, and the UVA NCI Comprehensive Cancer Center, Medicine- Hematology and Oncology

Primary Location

UVA Div. of Hematology-Oncology
PO Box 800716
Charlottesville, VA 22908

Primary Phone Number

434.924.9637

Fax Number

434.243.6086

[email protected]

Bio & Overview

Dr. Williams was recognized in 2023 with the Master Clinician Award in the UVA School of Medicine. He is an Emeritus member of the Lymphoma Research Foundation’s Scientific Advisory Board and was the inaugural Chair of their Mantle Cell Consortium. He was awarded the inaugural LRF Mantle Cell Lymphoma Leadership Award in 2021 and honored by establishment of the Dr. Michael Williams Abstract Achievement Award for MCL Research. He is a member of the U.S. Eastern Cooperative Oncology Group Lymphoma Core Committee, and of the European Mantle Cell Lymphoma Network. Dr. Williams is past Chair of the Hematology Subspecialty Board of the American Board of Internal Medicine, a past member of the ABIM Council, and currently serves on ABIM’s Hematology Longitudinal Knowledge Assessment Committee. He serves on the editorial board of the Journal of Clinical Oncology and as Associate Editor for Hematologic Malignancies for the NEJM Group Journal Watch Oncology and Hematology. He contributes regularly to national and international programs in research and education for lymphoma and CLL.

Academic Information

Department: Medicine- Hematology and Oncology

Academic Title: Associate Professor

Primary Education

BS, Botany, Ohio State University, 1973
Clinical Fellowship, Hematology, University of Virginianull
Clinical Fellowship, Oncology, University of Virginianull
MD, Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 1979
Residency, Internal Medicine, University of Virginianull
SM, Microbiology, Harvard University School of Public Health, Boston, MA, 1975

Other Appointments

Associate Professor, Medicine
Postdoctoral Researcher, Medicine- Cardiovascular Medicine

Other Affiliations

Member, Immunology/Immunotherapy Program

Research Interests

Dr. Williams’ patient care and research interests include clinical trials and translational science for mantle cell lymphoma, other non-Hodgkin lymphomas and CLL, with a focus on targeted agents and immuno-therapeutics.

Selected Publications

2024

Kahl, B. S., Jegede, O. A., Peterson, C., Swinnen, L. J., Habermann, T. M., Schuster, S. J., . . . Williams, M. E. (2024). Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 42(7). doi:10.1200/JCO.23.01912

2023

Ayers, E., Canderan, G., Williams, M. E., Keshavarz, B., Portell, C. A., Wilson, J. M., & Woodfolk, J. A. (2023). In-depth cellular and humoral dynamics of the response to COVID-19 vaccine booster in patients with chronic B-cell neoplasms. BLOOD CANCER JOURNAL, 13(1). doi:10.1038/s41408-023-00884-w

Jayappa, K. D., Tran, B., Gordon, V. L., Morris, C., Saha, S., Farrington, C. C., . . . Narla, G. (2023). PP2A modulation overcomes multidrug resistance in chronic lymphocytic leukemia via mPTP-dependent apoptosis. JOURNAL OF CLINICAL INVESTIGATION, 133(13). doi:10.1172/JCI155938

McLaughlin, P., Grillo-Lopez, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., . . . Dallaire, B. K. (2023). Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program (Reprinted from vol 16, pg 2825-2833, 1998). JOURNAL OF CLINICAL ONCOLOGY, 41(2), 154-162. doi:10.1200/JCO.22.02403

2022

Rusconi, C., Cheah, C. Y., Eyre, T. A., Tucker, D., Klener, P., Gine, E., . . . Visco, C. (2022). Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse. BLOOD, 140(17), 1907-1916. Retrieved from https://www.webofscience.com/

2021

Portell, C. A., Wages, N. A., Kahl, B. S., Budde, L. E., Chen, R. W., Cohen, J. B., . . . Williams, M. E. (2022). Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma. BLOOD ADVANCES, 6(5), 1490-1498. doi:10.1182/bloodadvances.2021005357

Jayappa, K. D., Gordon, V. L., Morris, C. G., Wilson, B., Shetty, B. D., Cios, K. J., . . . Weber, M. J. (2021). Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL. BLOOD ADVANCES, 5(17), 3497-3510. doi:10.1182/bloodadvances.2020003944

Isaac, K. M., Portell, C. A., & Williams, M. E. (2021). Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management. CURRENT ONCOLOGY REPORTS, 23(9). doi:10.1007/s11912-021-01094-y

Williams, M. E. (2021). Mantle cell lymphoma continues to surprise, and inform!. BLOOD, 137(23), 3158-3160. doi:10.1182/blood.2020010622

2018

Mock, J., Kunk, P. R., Palkimas, S., Sen, J. M., Devitt, M., Horton, B., . . . Maitland, H. (2018). Risk of Major Bleeding with Ibrutinib. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 18(11), 755-761. doi:10.1016/j.clml.2018.07.287

2017

Giulino-Roth, L., O'Donohue, T., Chen, Z., Bartlett, N. L., LaCasce, A., Martin-Doyle, W., . . . Leonard, J. P. (2017). Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. BRITISH JOURNAL OF HAEMATOLOGY, 179(5), 739-747. doi:10.1111/bjh.14951

Jayappa, K. D., Portell, C. A., Gordon, V. L., Capaldo, B. J., Bekiranov, S., Axelrod, M. J., . . . Weber, M. J. (2017). Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL (vol 14, pg 933, 2017). BLOOD ADVANCES, 1(19), 1537. doi:10.1182/bloodadvances.2017011148

Wages, N. A., Portell, C. A., Williams, M. E., Conaway, M. R., & Petroni, G. R. (2017). Implementation of a Model-Based Design in a Phase Ib Study of Combined Targeted Agents. CLINICAL CANCER RESEARCH, 23(23), 7158-7164. doi:10.1158/1078-0432.CCR-17-1069

Jayappa, K. D., Portell, C. A., Gordon, V. L., Capaldo, B. J., Bekiranov, S., Axelrod, M. J., . . . Weber, M. J. (2017). Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. BLOOD ADVANCES, 1(14), 933-946. doi:10.1182/bloodadvances.2016004176

Roth, L. G., O'Donohue, T., Chen, Z., Bartlett, N., Martin‐Doyle, W., Barth, M. J., . . . Leonard, J. P. (2017). OUTCOMES OF ADULTS, ADOLESCENTS, AND CHILDREN WITH PRIMARY MEDIASTINAL B‐CELL LYMPHOMA TREATED WITH DOSE‐ADJUSTED EPOCH‐R THERAPY: a MULTICENTER RETROSPECTIVE ANALYSIS. Hematological Oncology, 35(S2), 61-62. doi:10.1002/hon.2437_48

Martin, P., Chen, Z., Cheson, B. D., Robinson, K. S., Williams, M., Rajguru, S. A., . . . Leonard, J. P. (2017). Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 178(2), 250-256. doi:10.1111/bjh.14667

2016

Nowakowski, G. S., Blum, K. A., Kahl, B. S., Friedberg, J. W., Baizer, L., Little, R. F., . . . Smith, S. M. (2016). Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 108(12). doi:10.1093/jnci/djw257

Williams, M. E., Hong, F., Gascoyne, R. D., Wagner, L. I., Krauss, J. C., Habermann, T. M., . . . Kahl, B. S. (2016). Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. BRITISH JOURNAL OF HAEMATOLOGY, 173(6), 867-875. doi:10.1111/bjh.14007

Martin, P., Maddocks, K., Leonard, J. P., Ruan, J., Goy, A., Wagner-Johnston, N., . . . Blum, K. A. (2016). Postibrutinib outcomes in patients with mantle cell lymphoma. BLOOD, 127(12), 1559-1563. doi:10.1182/blood-2015-10-673145

2015

Kenkre, V. P., Hong, F., Cerhan, J. R., Lewis, M., Sullivan, L., Williams, M. E., . . . Kahl, B. S. (2016). Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. CLINICAL CANCER RESEARCH, 22(4), 821-826. doi:10.1158/1078-0432.CCR-15-1848

Wang, M. L., Blum, K. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., . . . Rule, S. (2015). Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. BLOOD, 126(6), 739-745. doi:10.1182/blood-2015-03-635326

Wages, N. A., Conaway, M. R., Slingluff, C. L. J., Williams, M. E., Portell, C. A., Hwu, P., & Petroni, G. R. (2015). Recent developments in the implementation of novel designs for early-phase combination studies. ANNALS OF ONCOLOGY, 26(5), 1036-1037. doi:10.1093/annonc/mdv075

Fogli, L. K., Williams, M. E., Connors, J. M., Reid, Y., Brown, K., & O'Connor, O. A. (2015). Development and characterization of a Mantle Cell Lymphoma Cell Bank in the American Type Culture Collection. LEUKEMIA & LYMPHOMA, 56(7), 2114-2122. doi:10.3109/10428194.2014.970548

Wagner, L. I., Zhao, F., Hong, F., Williams, M. E., Gascoyne, R. D., Krauss, J. C., . . . Kahl, B. S. (2015). Anxiety and Health-Related Quality of Life Among Patients With Low-Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT). JOURNAL OF CLINICAL ONCOLOGY, 33(7), 740-748. doi:10.1200/JCO.2014.57.6801

2014

Kahl, B. S., Hong, F., Williams, M. E., Gascoyne, R. D., Wagner, L. I., Krauss, J. C., . . . Horning, S. J. (2014). Rituximab Extended Schedule or Re-Treatment Trial for Low-Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402. JOURNAL OF CLINICAL ONCOLOGY, 32(28), 3096-+. doi:10.1200/JCO.2014.56.5853

2013

Cobbold, M., De La Pena, H., Norris, A., Polefrone, J. M., Qian, J., English, A. M., . . . Engelhard, V. H. (2013). MHC Class I-Associated Phosphopeptides Are the Targets of Memory-like Immunity in Leukemia. SCIENCE TRANSLATIONAL MEDICINE, 5(203). doi:10.1126/scitranslmed.3006061

Goy, A., Sinha, R., Williams, M. E., Besisik, S. K., Drach, J., Ramchandren, R., . . . Witzig, T. E. (2013). Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study. JOURNAL OF CLINICAL ONCOLOGY, 31(29), 3688-+. doi:10.1200/JCO.2013.49.2835

Axelrod, M., Ou, Z., Brett, L. K., Zhang, L., Lopez, E. R., Tamayo, A. T., . . . Wang, M. L. (2014). Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma. LEUKEMIA, 28(2), 407-410. doi:10.1038/leu.2013.249

Jurczak, W., Rule, S., Martin, P., Auer, R., Kahl, B. S., Giza, A., . . . Wang, M. L. (2013). Inhibitor kinazy Brutona u chorych z nawrotowym lub opornym na leczenie chłoniakiem z komórek płaszcza – wyniki międzynarodowego, wieloośrodkowego, badania II fazy z ibrutynibem (PCI-32765) – EHA Encore. Acta Haematologica Polonica, 44(3), 314-318. doi:10.1016/j.achaem.2013.07.013

Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., . . . Blum, K. A. (2013). Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. NEW ENGLAND JOURNAL OF MEDICINE, 369(6), 507-516. doi:10.1056/NEJMoa1306220

Cheah, C. Y., George, A., Gine, E., Chiappella, A., Kluin-Nelemans, H. C., Jurczak, W., . . . Seymour, J. F. (2013). Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. ANNALS OF ONCOLOGY, 24(8), 2119-2123. doi:10.1093/annonc/mdt139

Brett, L. K., & Williams, M. E. (2013). Current and Emerging Therapies in Mantle Cell Lymphoma. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 14(2), 198-211. doi:10.1007/s11864-013-0230-z

Williams, M. E., Bernstein, S. H., Jares, P., Kahl, B. S., Witzig, T. E., & Gordon, L. I. (2013). Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop. LEUKEMIA & LYMPHOMA, 54(9), 1882-1890. doi:10.3109/10428194.2013.771400

Williams, M. E. (2013). Transplantation for mantle cell lymphoma: is it the right thing to do?. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 568-574. doi:10.1182/asheducation-2013.1.568

2011

Jacobus, S. J., Kumar, S., Uno, H., Van Wier, S. A., Ahmann, G. J., Henderson, K. J., . . . Fonseca, R. (2011). Impact of high-risk classification by FISH: an Eastern Cooperative Oncology Group (ECOG) study E4A03. BRITISH JOURNAL OF HAEMATOLOGY, 155(3), 340-348. doi:10.1111/j.1365-2141.2011.08849.x

Fowler, N., Kahl, B. S., Lee, P., Matous, J. V., Cashen, A. F., Jacobs, S. A., . . . Cheson, B. D. (2011). Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study. JOURNAL OF CLINICAL ONCOLOGY, 29(25), 3389-3395. doi:10.1200/JCO.2010.32.1844

Mohr, M. R., Erdag, G., Shada, A. L., Williams, M. E., Slingluff, C. L. J., & Patterson, J. W. (2011). Two Patients With Hailey-Hailey Disease, Multiple Primary Melanomas, and Other Cancers. ARCHIVES OF DERMATOLOGY, 147(2), 211-215. doi:10.1001/archdermatol.2010.445

2010

Williams, M. E., Connors, J. M., Dreyling, M. H., Gascoyne, R. D., Kahl, B. S., Leonard, J. P., . . . Wilson, W. H. (2011). Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. LEUKEMIA & LYMPHOMA, 52(1), 24-33. doi:10.3109/10428194.2010.532893

Williams, M. E., Dreyling, M., Winter, J., Muneer, S., & Leonard, J. P. (2010). Management of Mantle Cell Lymphoma: Key Challenges and Next Steps. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 10(5), 336-346. doi:10.3816/CLML.2010.n.066